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AbstrAct
Objective To investigate the development in the 
number of applications for authorisation of clinical trials 
of medicines (CTAs) submitted annually to national 
competent authorities in 10 Western European member 
states of the European Union from 2007 to 2015.
Design Registry study.
Setting Data from national competent authorities.
Participants Germany, Italy, Spain, France, the UK, 
Belgium, the Netherlands, Austria, Denmark and Sweden. 
Inclusion criteria were Western European member states 
of the European Union, receiving more than 200 CTAs per 
year.
Outcome measures Summarised number of CTAs and 
distribution of CTAs by type of sponsor (commercial or 
non-commercial) and trial phase (I–IV). Average annual 
growth rates (AAGRs) based on linear regressions. Data 
were evaluated 2007–2011 and 2012–2015 to compare 
findings with the European Commission’s statement of a 
25% decrease in CTAs in the EU from 2007 to 2011.
Results From 2007 to 2011, the summarised number 
of CTAs decreased significantly (AAGR −3.9% (p=0.02)), 
primarily due to a decrease in commercially sponsored 
CTAs. From 2012 to 2015, the change was insignificant 
(AAGR 2.6% (p=0.27)), however with a 10% increase from 
2014 to 2015 after stagnation from 2012 to 2014. Overall, 
the number of CTAs and distribution by type of sponsor 
varied considerably between countries. No distinct trends 
were observed when evaluating CTAs by type of trial 
phase.
Conclusions This study found a significant decrease in 
the number of CTAs in Western Europe from 2007 to 2011 
(AAGR −3.9%). This development is possibly attributable 
to several factors such as the European Clinical Trials 
Directive, national and local political decisions, and a 
potential global shift in clinical trial activity. From 2014 
to 2015, the number of CTAs increased markedly (10%). 
However, it is yet too soon to determine if this constitutes a 
transient fluctuation or a new trend.
IntroductIon
Approximately 4000 clinical trials of medi-
cines are authorised annually in the European 
Union (EU).1 The majority of these trials are 
conducted in Western European countries, 
but the number of clinical trials of medicines 
in this region seems to decrease. According 
to the European Commission, the number of 
applications for authorisation of clinical trials 
of medicines (CTAs) decreased by 25% from 
2007 to 2011 in the EU as a whole.2 A decline 
in clinical trial activity may have negative 
implications for patients, healthcare profes-
sionals and society, as clinical trials are central 
in discovering new medical treatments and 
improvement of medical care. Therefore, 
several initiatives have emerged in the last five 
to eight years to improve conditions for the 
conduct of clinical trials in Europe. Among 
these, the Voluntary Harmonisation Proce-
dure was implemented in 2009 to improve 
regulatory time to approval and make the 
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Research
Strengths and limitations of this study
 ► This registry study is one of only few studies 
presenting detailed data on clinical trial activity in 
Western Europe.
 ► Data on the annual number of applications for clinical 
trials of medicines in 10 countries were included; as 
these countries are responsible for the vast majority 
of clinical trials of medicines conducted in Western 
Europe, the data represent Western Europe as a 
whole.
 ► The number of clinical trial applications does not 
precisely reflect the number of clinical trials of 
medicines conducted as some applications are 
rejected, some trials are never conducted, and in 
multinational trials, multiple applications represent 
one clinical trial.
 ► The summarised number of clinical trial applications 
in 2015 is only an approximation as data from 2015 
were not available from one out of the 10 countries 
included.
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application procedure in multinational trials easier for 
the sponsor.3 Furthermore, standard contracts have been 
developed, and evolvement of national disease specific 
research networks is a priority in some countries.
Few studies have examined the development in CTAs 
in Western Europe. One of these studies found that from 
2001 to 2009, the number of CTAs decreased in four out of 
the six Western European countries that are responsible 
for the highest number of clinical trials of medicines.4 
Another study found that the number of CTAs decreased 
in three out of four Scandinavian countries in the period 
2007–2011.5 To our knowledge, no previous study has 
examined the development in the number of CTAs in 
Western Europe as a whole during the period 2007–2011 
or since 2011.
Accordingly, the objective of this study is to investi-
gate the development in the number of CTAs submitted 
annually to national competent authorities in 10 Western 
European member states of the EU from 2007 to 2015. 
Specifically, the aims are to (1) evaluate the development 
in the summarised number of CTAs, (2) evaluate the 
development in the number of CTAs by type of sponsor 
and trial phase also taking into account the develop-
ment in the individual countries and (3) determine the 
percentage change in the summarised number of CTAs 
from 2007 to 2011 to compare our findings with the Euro-
pean Commission’s statement of a 25% decrease in the 
number of CTAs in the EU during this period.
Methods
We evaluated the number of CTAs submitted annually 
to the national competent authorities in the following 
Western European EU member states in the period 
2007–2015: Germany, Italy, Spain, France, the UK, 
Belgium, the Netherlands, Austria, Denmark and 
Sweden. The inclusion criteria were Western European 
EU member states, receiving more than 200 CTAs per 
year. By including these countries, data represent the 
development in Western Europe as a whole as these 
countries together account for approximately 90% of all 
CTAs in Western Europe. The distribution of CTAs by 
type of sponsor (commercial or non-commercial) and 
trial phase (I–IV) was determined. However, data on 
type of trial phase were not available from France, and 
phase II and III clinical trials are registered together by 
the UK and could therefore not be separated. The type 
of sponsor and trial phase were defined according to the 
European Commission’s application form for the request 
for authorisation of a clinical trial, which is completed by 
the sponsor when applying for authorisation of a clin-
ical trial.6–8 Data sources appear in online supplementary 
appendix 1. Data were primarily extracted from publicly 
available annual reports and statistics published on the 
websites of the national competent authorities. The 
remaining data were extracted from reports published by 
consulting firms and supplied by the national competent 
authorities by email.
Data were evaluated with regard to two periods: 
2007–2011 and 2012–2015. The period 2007–2011 was 
specifically selected to compare our findings with the 
European Commission’s statement of a 25% decrease in 
the number of CTAs in the EU during this period. The 
development in CTAs by type of sponsor and trial phase in 
each country was described using average annual growth 
rates (AAGRs), inspired by Hartmann (table 1).4 The total 
number of CTAs for all countries was addressed as the 
summarised number of CTAs to specify that the number 
refers to a summation of CTAs of which some refer to 
the same clinical trial. In contrast to the other countries 
included, the number of CTAs in Italy in 2015 is not yet 
available from the Italian national competent authorities. 
Therefore, we estimated this number to complete the 
data of the summarised number of CTAs for all countries 
in 2015 (online supplementary appendix 2).
statistics
Univariate linear regression analysis was used to eval-
uate the development in CTAs over time. AAGRs for 
the summarised number of CTAs and number of CTAs 
in each country were calculated based on the univar-
iate linear regressions (AAGR=100 × (C[n] / (C[n-1] 
−1)), where C[n] is the number of CTAs in year n). The 
R2 values and p values of the trendlines were determined 
to evaluate potentially significant changes in the number 
of CTAs over time. p Values ≤0.05 were considered statis-
tically significant. The statistical analysis was also applied 
to the subsets of data regarding type of sponsor and trial 
phase. Data were analysed using Statistical Analysis System 
(SAS) V.9.4.
The percentage change in the summarised number 
of CTAs from 2007 to 2011 was determined using the 
observed values (not the estimated values on the trend 
line) to make comparison with the European Commis-
sion’s statement of a 25% decrease in the number of 
CTAs in the EU possible.
results
The summarised number of CTAs did not change 
significantly during the observation period as a whole 
(2007–2015) (AAGR −1.4% (p=0.08)) (table 1). As illus-
trated in figure 1, between 6101 and 7084 CTAs were 
submitted annually in the period 2007–2015. On average, 
74% of the CTAs were commercially sponsored and 26% 
were non-commercially sponsored with only little vari-
ability (SD 0.9%). The development in the number of 
CTAs in the individual countries appears in figures 2a, b 
and c. Overall, the number of CTAs and the distribution 
of CTAs by type of sponsor varied considerably between 
countries. Phase III clinical trials were the most common 
type of trial applied for in each country, constituting 
between 34% and 45% of all submitted CTAs (figure 3).
the period 2007–2011
The summarised number of CTAs decreased significantly 
from 2007 to 2011 with an AAGR of −3.9% (p=0.02) 
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Table 1 Average annual growth rates (AAGRs) of the number of clinical trial applications (CTAs) by type of sponsor and trial 
phase in 10 Western European countries+
Country Total CTAs†
CTAs by type of sponsor CTAs by type of trial phase
Commercially 
sponsored CTAs
Non-commercially 
sponsored CTAs
Phase I 
CTAs
Phase II 
CTAs
Phase III 
CTAs
Phase IV 
CTAs
AAGRs in the period 2007–2015 (%)
  All countries −1.4 −1.5 −1.1 −2.8* −2.2* −0.9 −4.3*
  Germany −3.7* −3.2* −6.0** −5.9* −3.3* −1.8* −5.7*
  Italy‡ −3.9* −1.6 −8.5* 9.6* −6.1* −5.0* −9.5*
  Spain 2.3* 1.9 3.5 5.9** 1.2 3.5* −3.2*
  France 0.9 0.9 0.9 – – – –
  The UK§ −1.5 −1.2 −2.5 −5.1**     2.5 −8.6*
  Belgium 0.4 −0.9 6.6* −0.9 −0.8 1.5 2.6
  The Netherlands¶ −1.1 −1.2 −1.1 −0.6 1.8 −1.4 −2.9
  Austria −2.8* −3.7 −0.5 −1.6 −5.4* −1.7 −4.0
  Denmark 2.1 −1.8 9.5** 194 4.4 4.0 4.3
  Sweden −5.6** −7.3** −0.2 −17** −3.9 −3.5* −4.5
AAGRs in the period 2007–2011 (%)
  All countries −3.9* −4.7* −1.5 −2.4 −1.1 −2.0 −6.4
  Germany −2.4 −2.2 −3.3* −3.7 −1.8 −2.1 −3.7
  Italy‡ −5.6 −4.4 −7.6 14.4 −5.4 −7.6 −6.4
  Spain 2.3 −2.1 18.6* 5.5 3.0 1.0 0.7
  France −6.0* −6.0* −6.0* – – – –
  The UK§ −6.3* −6.5* −5.7 −4.4     −3.8 −13*
  Belgium −3.9 −4.7 0.6 −3.8 −5.1 −1.5 −9.1
  The Netherlands¶ −4.2 −6.1 −1.2 −4.4 −1.9 −4.3 −7.4
  Austria −2.0 −1.9 −2.4 9.4 −0.5 −1.2 −9.8
  Denmark −1.8 −8.7* 14.1* – – – –
  Sweden −7.9* −11* 1.7 −13** −4.3 −8.1* −6.4
AAGRs in the period 2012–2015 (%)
  All countries 2.6 3.1 1.1 −0.2 −5.6 −2.9 0.8
  Germany −0.2 0.0 −1.3 −3.4 −2.2 2.5 7.6
  Italy‡ −1.7 −1.7 −1.8 17.2 −9.3 −9.1 −24
  Spain 2.3 4.4 −4.3 3.9 −1.8 5.1 0.4
  France 7.3 7.4 7.3 – – – –
  The UK§ 3.9 4.5 1.7 −1.4     5.2* 5.0
  Belgium 5.0 4.3 7.7 2.7 0.2 7.3 14.2
  The Netherlands¶ 2.3 6.7 −3.7 4.6 16.2 0.5 4.8
  Austria −1.0 1.6 −6.9 2.9 −7.5 0.4 −1.8
  Denmark 7.1 6.7 7.7 14.5 5.7 5.1 6.3
  Sweden 0.0 −2.6 7.3* 12.0 −6.2 −3.5* 5.4
+Data from Italy, France and Spain refer to the numbers of authorised clinical trials and not clinical trial applications.
†Phases can overlap. Thus, the summarised number of clinical trial applications for all trial phases is not necessarily equal to the total number 
of clinical trial applications registered.
‡AAGR in the period 2011–2015 for Italy only includes data from 2011 to 2014.
§In the UK, phase II and III clinical trials are registered together and could therefore not be separated.
¶Some clinical trials are not specified by the sponsor in regards to the trial phase. The national competent authorities of Italy and the 
Netherlands have registered these as not specified. These trials are not included in this table.
*Indicates p<0.05.
**Indicates p<0.001.
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Figure 1 The summarised number of clinical trial applications in 10 Western European countries. The 10 included countries are 
Germany, Italy, Spain, France, the UK, Belgium, the Netherlands, Austria, Denmark and Sweden. The summarised number of 
clinical trial applications for 2015 is estimated as data from Italy regarding 2015 is not yet available from the national competent 
authorities. The number of clinical trials authorised in Italy in 2015 is therefore estimated.
(table 1). The percentage change was 12%. As illustrated 
by figure 2a and table 1, all countries except Spain expe-
rienced a decrease in the number of CTAs. Especially 
France, the UK and Sweden experienced a great decline 
with an AAGR of −6.0% (p=0.02), −6.3% (p=0.01) and 
−7.9% (p=0.02), respectively.
The decrease in the summarised number of CTAs was 
primarily due to a decrease in commercially sponsored 
CTAs, which decreased significantly (AAGR −4.7%, 
p=0.01), whereas the number of non-commercially spon-
sored CTAs decreased insignificantly (AAGR −1.5%, 
p=0.30). All countries experienced a decrease in commer-
cially sponsored CTAs, and six out of 10 a decrease in 
non-commercially sponsored CTAs. It is noteworthy 
that the modest summarised decrease in non-commer-
cially sponsored CTAs was due to a considerable increase 
in non-commercially sponsored CTAs in Spain and 
Denmark (AAGR 18.6% (p=0.01) and 14.1% (p=0.04), 
respectively), whereas other countries such as Germany 
and France experienced a marked decline (AAGR −3.3% 
(p=0.04) and −6.0% (p=0.03), respectively) (figure 2c and 
table 1). The summarised number of CTAs decreased 
within all trial phases, however not significantly. No other 
trends in the development of CTAs by type of trial phase 
were observed.
the period 2012–2015
From 2012 to 2015, the summarised number of CTAs 
did not change significantly (AAGR 2.6% (p=0.27)). The 
summarised number of CTAs was stable between 6101 
and 6250 CTAs annually from 2012 to 2014, whereas it 
increased considerably from 2014 to 2015 (10%). No 
countries experienced a significant change in the number 
of CTAs during the period (table 1). However, from 2014 
to 2015, the number of CTAs increased in nine out of 
nine countries, and seven out of nine countries experi-
enced an increase in both commercially sponsored and 
non-commercially sponsored CTAs (figures 2a, b and c).
No trends were observed in the development of CTAs 
by type of trial phase from 2012 to 2015. There was an 
increase in the number of positive AAGRs regarding 
all trial phases in this period compared with the period 
2007–2011.
dIscussIon
This study showed that the development in the number 
of CTAs in Western Europe changed considerably during 
the period 2007–2015. From 2007 to 2011, nine out of 
10 countries experienced a decrease in the number of 
CTAs, and the summarised number of CTAs decreased 
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Figure 2a The total number of clinical trial applications in 10 Western European countries. AAGRs, average annual growth 
rates. Data from Italy, France and Spain refer to the numbers of authorised clinical trials and not clinical trial applications. The 
AAGRs, R2s and p values are based on linear regression lines (not shown).
significantly with an AAGR of −3.9%. This decrease was 
followed by stagnation from 2012 to 2014 and subse-
quently a marked increase in the summarised number of 
CTAs of 10% from 2014 to 2015.
The negative development in the summarised number 
of CTAs from 2007 to 2011 was primarily due to a decrease 
in commercially sponsored CTAs (AAGR −4.7%). In 
addition, it was due to a decrease within all trial phases. 
According to the European Commission, the number of 
CTAs supposedly decreased by 25% in the EU as a whole 
from 2007 to 2011.2 In this study, the percentage change 
in the summarised number of CTAs was 12% during this 
period. Thus, one would expect a decrease in the number 
of CTAs in the Eastern European EU member states as 
well. Poland, the Czech Republic, Rumania and Hungary 
together with the countries included in this study 
account for the vast majority of clinical trials of medicines 
conducted in the EU. However, these four Eastern Euro-
pean EU member states did not experience a decrease in 
CTAs from 2007 to 2011 (refs 9–11, personal communi-
cation with the national competent authorities of Poland 
and Hungary). Consequently, our findings are more 
consistent with the 12% decrease from 2007 to 2010 also 
reported by the European Commission.2
strengths and limitations of this study
This is one of only few studies presenting detailed data 
on clinical trial activity in Western Europe. The study, 
therefore, adds information to the understanding of the 
clinical trial landscape in Europe. As the exact number 
of clinical trials of medicines and other clinical trials 
conducted (e.g. of medical devices and surgical proce-
dures) is not publicly known, the development in the 
number of CTAs is one of the best indicators of clinical 
trial activity alongside data from clinical trial registries 
such as  ClinicalTrials. gov, the WHO International Clin-
ical Trials Registry Platform and the EU Clinical Trials 
Register. However, the data presented in this study do not 
precisely reflect the number of clinical trials of medicines 
conducted. First, some CTAs are rejected, and some trials 
are never conducted. Therefore, the number of CTAs in 
a country exceeds the actual number of trials. Second, 
multinational trials include CTAs in multiple countries. 
According to the European Commission, approximately 
24% of all clinical trials of medicines applied for in the 
EU are multinational trials including CTAs in at least two 
member states.2 An increase in the summarised number 
of CTAs one year might be due to applications from a 
few large multinational trials and not an increase in the 
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Figure 2b The number of commercially sponsored clinical trial applications in 10 Western European countries. AAGRs, 
average annual growth rates. Data from Italy, France and Spain refer to the numbers of authorised clinical trials and not 
clinical trial applications. The national competent authorities of France states that approximately two-thirds of the clinical trials 
authorised annually in France are commercially sponsored, and one-third is non-commercially sponsored. The exact number of 
clinical trials by type of sponsor is unknown. The AAGRs, R2s and p values are based on linear regression lines (not shown).
total number of clinical trials of medicines. Particularly 
commercially sponsored clinical trials are multinational, 
and therefore, the summarised number of CTAs for these 
trials reflects the true number of clinical trials of medi-
cines less accurately compared with non-commercially 
sponsored CTAs. Still, the summarised number of CTAs is 
informative for the clinical trial activity; it makes a differ-
ence if a sponsor applies for conduction of a clinical trial 
in several European countries or only a few. Third, data 
regarding type of trial phase depend on information 
given by the sponsor in the application form. In these 
forms, more than one type of trial phase can be declared 
so that the application represents more than one type of 
phase.
In this study, six Western European EU member states 
were not included (Portugal, Ireland, Finland, Greece, 
Luxembourg and Malta). Moreover, Switzerland, Norway 
and Iceland were not included as these Western Euro-
pean countries are not EU member states. However, these 
nine countries together account for only approximately 
10% of all CTAs in Western Europe.5 12–16 Therefore, we 
believe that the data presented are representative for 
Western Europe as a whole.
Data on type of trial phase were limited in this study. It 
was not possible to gain data from France on the distri-
bution of CTAs by type of trial phase. Furthermore, it 
was not possible to evaluate the distribution of CTAs by 
type of sponsor with regard to trial phase as these data 
were not available from all countries and therefore not 
included. It should be noted that the summarised number 
of CTAs in 2015 is only an approximation as described in 
online supplementary appendix 2.
We used univariate linear regression analysis to evaluate 
the development in the number of CTAs over time. There-
fore, we assumed that the development in the number 
of CTAs was linear over time which may not be the case. 
Furthermore, only few observations were present. Factors 
such as the financial crisis may explain some of the varia-
tion in the number of CTAs. However, such factors were 
not included in the current analysis due to few observa-
tions.
Possible explanations and comparison with other studies
Many stakeholders have addressed that the European 
Clinical Trials Directive (EU 2001/20/EC) has had 
a negative effect on the conduction of clinical trials in 
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Figure 2c The number of non-commercially sponsored clinical trial applications in 10 Western European countries. AAGRs, 
average annual growth rates. Data from Italy, France and Spain refer to the numbers of authorised clinical trials and not 
clinical trial applications. The national competent authorities of France states that approximately two-thirds of the clinical trials 
authorised annually in France are commercially sponsored, and one-third is non-commercially sponsored. The exact number of 
clinical trials by type of sponsor is unknown. The AAGRs, R2s and p values are based on linear regression lines (not shown).
Europe. Especially stakeholders involved in non-commer-
cially sponsored trials have emphasised this.17–20 However, 
the cause for the observed decrease in CTAs is possibly 
multifactorial, and at least three other contributing 
factors should be considered: national and local political 
decisions, a potential global shift in clinical trial activity 
and the financial crisis initiated in 2007.
National and local political decisions influence the 
clinical trial landscape alongside EU regulations. For 
example, in contrast to other countries, Denmark had a 
stable increase in the number of non-commercially spon-
sored CTAs from 2007 to 2015, and the number was stable 
during the implementation of the directive.21 As pointed 
out by Berendt et al, the presence of publicly funded good 
clinical practice units presumably mitigated the negative 
effect of the directive as these units provide free assis-
tance to academic researchers doing clinical research. 
Similar to Denmark, Italy took specific actions to support 
academic research following the implementation of the 
directive, and Italy experienced an increase in non-com-
mercially sponsored CTAs every year from 2004 to 2008.22 
In 2009 though, a new decree demanded a higher level of 
insurance coverage for many academic institutions.4 This 
might explain the decrease in non-commercially spon-
sored CTAs in Italy from 2009 onwards. Thus, national 
and local political decisions can have a considerable 
impact on the clinical trial landscape, and it is likely that 
national initiatives, or the lack of such, have contributed 
to the decrease in CTAs from 2007 to 2011.
A global shift in clinical trial activity may also partly 
explain the decrease. Six recent studies analysed the global 
distribution of clinical trials using data from publicly avail-
able trial registries.23–28 Five of these six studies found that 
regions such as China, India and Japan hold an increasing 
share of the total number of clinical trials registered 
worldwide. The remaining study did not address this 
question but found that more than a quarter of clinical 
trials registered in  ClinicalTrials. gov recruit participants 
in non-high-income countries.25 Other studies have also 
supported the hypothesis of a global shift. One study 
found that the number of active FDA-regulated investi-
gators based outside the USA grew by 15% annually from 
2002 to 2006, while the number of US-based FDA-regu-
lated investigators declined.29 Regarding European trials, 
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Figure 3 The average annually number of clinical trial 
applications by trial phase in nine Western European 
countries. The average annually number of clinical trial 
applications is based on data from 2007 to 2015. Phases 
can overlap. Thus, the summarised number of clinical trial 
applications for all trial phases is not necessarily equal to 
the total number of clinical trial applications registered. In 
the UK, phase II and III clinical trials are registered together 
and could therefore not be separated. The average number 
of clinical trial applications for phase II and III in the UK is 
590. Data from Denmark regarding the number of clinical 
trial applications by trial phase are only from 2010 to 2015. 
Data from Italy and Spain refer to the numbers of authorised 
clinical trials and not clinical trial applications.
the number of patients recruited from Asian, Pacific and 
Middle Eastern countries in trials used for marketing 
authorisation applications to the European Medicines 
Agency increased substantially from 2005 to 2011.30 The 
financial crisis may have contributed to the decrease in 
CTAs in Europe and encouraged a shift to regions in 
which trial costs are lower. However, several crucial issues 
regarding a potential shift in clinical trial activity remain 
unclear. First, it is unclear whether the number of clin-
ical trials is decreasing overall in traditional regions, or if 
other regions are just conducting more trials than before. 
Second, it is unclear whether the change in trial activity is 
primarily due to a shift in commercially sponsored trials or 
an increase in non-commercially sponsored trials. Third, 
it is possible that the increasing level of registration of 
clinical trials in trial registries leaves a biased impression 
of a global shift. Moreover, it is unclear if the potential 
global shift in clinical trial activity applies to clinical trials 
of medicines, as studies on global trial activity investigate 
clinical trials in general and not exclusively clinical trials 
of medicines.
After seven years of decrease and stagnation, the number 
of CTAs in Western Europe is now markedly increasing. 
This seems promising for the clinical trial landscape of 
Europe. However, it is yet unclear if this constitutes a 
transient fluctuation or a new trend. The increase in the 
number of CTAs in 2015 might simply result from a few 
large multinational trials. However, the positive develop-
ment might continue due to the initiatives implemented 
to better the conditions for the conduct of clinical trials 
in Europe. Since the implementation of the Voluntary 
Harmonisation Procedure in 2009, the number of CTAs 
undergoing this procedure has increased considerably, 
and in 2015, 23% of all multinational clinical trials of 
medicines underwent the procedure.31 This may have led 
to a faster regulatory time to approval and an increase 
in the number of multinational trials conducted in the 
EU. However, to our knowledge, this has not yet been 
investigated. A positive development in the number 
of CTAs may also be attributed to sponsors and admin-
istrative stakeholders becoming increasingly familiar 
with the new procedures that followed the EU directive. 
Moreover, the impact of the financial crisis on the phar-
maceutical industry and national governments seems to 
be diminishing. However, it should be emphasised that 
the development in the clinical trial landscape is very 
complex with many global, national and local issues of 
influence.
conclusIon
This study found a significant decrease in the number 
of CTAs in Western Europe from 2007 to 2011 (AAGR 
−3.9%). This development is possibly attributable to 
several factors such as the European Clinical Trials Direc-
tive, national and local political decisions, and a potential 
global shift in clinical trial activity. From 2014 to 2015, 
the number of CTAs increased markedly (10%) after a 
period of stagnation from 2012 to 2014. Overall, there 
seems to be a positive development in the clinical trial 
landscape of Western Europe. However, it is yet too soon 
to determine if this constitutes a transient fluctuation or 
a new trend.
This study was limited to evaluating the development in 
the number of CTAs in Western Europe. Further research 
on the development in the number of CTAs in other 
geographic regions is required to compare the activity of 
clinical trials of medicines globally. Also, it is relevant to 
evaluate commercially and non-commercially sponsored 
CTAs by type of trial phase and distribution of national 
and multinational trials. Moreover, it would be interesting 
to investigate other aspects of clinical trials of medicines 
conducted, for example, which type of products are inves-
tigated, which therapeutic areas are represented and how 
many study participants are included.
Numerous issues influence the number of clinical trials 
of medicines conducted and several initiatives may be 
considered to attract and retain clinical trials. Among 
these, development of uniform regulatory processes, 
elimination of unnecessary bureaucratic procedures and 
development of standard contracts should be a priority. 
Furthermore, on a national level, optimisation of clin-
ical trial units, evolvement of national disease-specific 
research networks and patient databases, availability of 
relevant information for the pharmaceutical industry on 
clinical trials and increased support for non-commercially 
sponsored clinical trials may be considered. However, 
knowledge of which factors influence the allocation of 
clinical trials is sparse, and a better understanding of this 
issue is important to improve the conditions for conduc-
tion of clinical trials and to attract and retain these 
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regionally. Qualitative studies such as interviews among 
sponsors and clinical trial personnel would be suitable to 
illuminate this issue.
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